食管癌的Fas配体表达及意义

The expression of Fas ligand in esophageal carcinoma and its clinic significance

目的 检验Fas配体在食管癌细胞的表达 ,及其与食管癌浸润淋巴细胞、与食管癌浸润与转移的关系和对病人术后生存的影响。方法 采用免疫组化方法检测 30例原发食管癌标本中Fas配体的表达 ,用CD4 5标记肿瘤浸润淋巴细胞。结果 76 6 %的标本有Fas配体的表达 ,且不同TNM分期的病人表达水平差异显著 ,Fas配体的表达与食管癌中肿瘤浸润淋巴细胞数呈负相关 ,但Fas配体的表达与病人术后生存无显著关系。结论 Fas配体的表达有利于食管癌逃避免疫攻击 。

Objective: To determine the expression of Fas ligand (FasL) in the patients with esophageal carcinoma and its clinic significance. Methods: The expression of FasL was measured by immunohistochemical technique in 30 patients with esophageal cancer. The numbers of tumor infiltrationg (TIL) were accounted by immunohistochemically stained CD45. Results: 76 6% of specimen expressed FasL. The difference of FasL expression was significant between each TNM stage. There was a negative correlation between the number of TIL and the expression of FasL. Conclusion: The expression of FasL in esophageal carcinoma may correlate with its invasion and metastasis.